Risk-Conferring Glutamatergic Genes and Brain Glutamate Plus Glutamine in Schizophrenia

Juan Bustillo, Veena Patel, Thomas R. Jones, Rex E. Jung, Nattida Payaknait, Clifford Qualls, José M. Cañive, Jingyu Liu, Nora I. Perrone‐Bizzozero, Vince D. Calhoun, Jessica A. Turner, Charles GasparovicFrontiers in Psychiatry 2017 · DOI

Abstract

Elevations in brain Glx (a combined measure of glutamate and glutamine) are a hallmark of schizophrenia, yet the underlying causes remain poorly understood. This study investigates whether common allelic variants of glutamate-related genes, known to increase the risk for schizophrenia, correlate with these neurochemical elevations. While overall glutamate risk scores did not differ significantly between patients and healthy controls, a distinct relationship emerged in younger patients. These findings suggest that genetic risk manifests as observable chemical imbalances primarily in the early stages of the illness, likely interacting with other genetic or environmental factors.

Introduction

The "glutamate hypothesis" of schizophrenia posits that the disorder is driven by dysfunction in glutamatergic neurotransmission, specifically an overabundance of glutamate in key brain regions. While large-scale genomic studies have identified specific single-nucleotide polymorphisms (SNPs) that increase disease risk, the functional link between these "risk genes" and actual brain chemistry has remained elusive. This study sought to bridge this gap by determining if a summary genetic risk score could predict brain levels of Glx measured via neuroimaging.

Methodology

The researchers employed a multimodal approach combining neuroimaging and genomics in a cohort of 56 clinically stable patients with schizophrenia and 67 healthy controls.

Neuroimaging and Spectroscopy

Proton Magnetic Resonance Spectroscopy ($^1$H-MRS) was performed using a 3-Tesla scanner to measure Glx levels in an axial slab of the brain. The analysis focused on both gray matter (GM) and white matter (WM) voxels. To ensure data integrity, the researchers controlled for tissue fraction and spectral quality (Cramer–Rao lower bounds).

Figure 1: (A) Voxel placement on a T2-weighted MRI. (B, C) Representative MRS spectra showing metabolite peaks like Glx and NAAc. (D) Correlation between Glx levels and gray matter fraction.

Genomic Risk Scoring

Using an Illumina 5M SNP array, summary risk scores were calculated based on odds ratios from the Psychiatric Genetics Consortium (PGC). Two categories were analyzed:

  1. Glutamate-related SNPs: Including genes such as GRM3, CLCN3, and SLC38A7.
  2. Calcium signaling SNPs: Including genes such as CACNA1C and CACNB2.

Data were analyzed using a PROC-MIXED repeated-measures model to account for multiple voxels per subject while controlling for age and tissue type.

Key Results

The Interaction of Age and Genetics

The most significant finding was a specific correlation between genetic risk and brain chemistry in younger patients (≤36 years). In this subgroup, higher glutamate-related risk scores directly predicted higher Glx levels in the gray matter ($p = 0.01$). This relationship was absent in older patients and healthy controls, suggesting that the genetic influence on glutamate metabolism may be most prominent early in the disease course or becomes obscured by chronic illness and medication over time.

Figure 2: Scatter plot illustrating the relationship between Glx levels and the Glutamate risk score, categorized by diagnosis and age. Note the positive slope specifically for the "Schizophrenia young" group (dashed red line).

Disease-Wide Elevations

Regardless of genetic risk scores, the schizophrenia group as a whole exhibited significantly higher Glx levels in both gray and white matter compared to healthy controls ($p < 0.001$). This indicates that while specific SNPs contribute to the chemical profile, they are part of a broader pathological process. Notably, the correlation was specific to glutamate-related genes; risk scores for calcium signaling genes did not show a similar relationship with Glx levels.

Discussion and Limitations

This study provides a "proof-of-principle" link between genetic predisposition and neurochemical reality. However, several limitations must be considered. The sample size, while robust for an MRS study, is relatively small for genetic association work. Additionally, due to the limitations of the SNP array used, only a subset of targeted glutamate-related genes could be measured.

Future research utilizing higher field strengths (e.g., 7-Tesla) could provide better spectral resolution to separate glutamate from glutamine. Furthermore, investigating epigenetic factors like DNA methylation may reveal how these risk genes are regulated, providing a more comprehensive view of the path from genotype to phenotype in schizophrenia.

Summary updated

Abstract

Elevations in brain Glx are in part, related to common allelic variants of glutamate-related genes known to increase the risk for schizophrenia. Since the glutamate risk scores did not differ between groups, some other genetic or environmental factors likely interact with the variability in glutamate-related risk SNPs to contribute to an increase in brain Glx early in the illness.
BibTeX
@inproceedings{bustillo2017risk,
  author = {Juan Bustillo and Veena Patel and Thomas R. Jones and Rex E. Jung and Nattida Payaknait and Clifford Qualls and José M. Cañive and Jingyu Liu and Nora I. Perrone‐Bizzozero and Vince D. Calhoun and Jessica A. Turner and Charles Gasparovic},
  title = {{Risk-Conferring Glutamatergic Genes and Brain Glutamate Plus Glutamine in Schizophrenia}},
  booktitle = {Frontiers in Psychiatry},
  year = {2017},
  doi = {10.3389/fpsyt.2017.00079},
}
Figure